Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection

International Journal of Antimicrobial Agents

Volumn 46, Issue 5, 2015, Pages 576-581

  Gehin, Martine ^a   Desnica, Boško ^b   Dingemanse, Jasper ^a  

^a ACTELION PHARMACEUTICALS LTD   (Switzerland)

^b Croatia   (Croatia)

Author keywords

Cadazolid; Clostridium difficile infection (CDI); Faecal exposure; Plasma; Systemic exposure

Indexed keywords

CADAZOLID; FLUCONAZOLE; LACTULOSE; MANNITOL; METRONIDAZOLE; VANCOMYCIN; ANTIINFECTIVE AGENT; OXAZOLIDINONE DERIVATIVE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANDIDURIA; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONSTIPATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG ELIMINATION; DRUG EXPOSURE; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GASTROINTESTINAL MUCOSA; HUMAN; HYPOPROTEINEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; MICROBIOLOGICAL EXAMINATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OPEN STUDY; PEPTOCLOSTRIDIUM DIFFICILE; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYSTEMIC THERAPY; VERY ELDERLY; ADOLESCENT; ADVERSE DRUG REACTION; CHEMISTRY; CLINICAL TRIAL; CLOSTRIDIUM INFECTIONS; FECES; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PLASMA; TIME FACTOR; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FECES; FEMALE; HUMANS; MALE; MIDDLE AGED; OXAZOLIDINONES; PLASMA; TIME FACTORS; YOUNG ADULT;

EID: 84946571667     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2015.07.015     Document Type: Article

References (15)

1. M. Kachrimanidou, and N. Malisiovas Clostridium difficile infection: a comprehensive review Crit Rev Microbiol 37 2011 178 187
2. J.T. Higa, and C.P. Kelly New drugs and strategies for management of Clostridium difficile colitis J Intensive Care Med 29 2013 190 199
3. C.P. Kelly, C. Pothoulakis, and J.T. LaMont Clostridium difficile colitis N Engl J Med 330 1994 257 262
4. M. Rupnik, M.H. Wilcox, and D.N. Gerding Clostridium difficile infection: new developments in epidemiology and pathogenesis Nat Rev Microbiol 7 2009 526 536
5. C. Pothoulakis Effects of Clostridium difficile toxins on epithelial cell barrier Ann N Y Acad Sci 915 2000 347 356
6. M. Riegler, R. Sedivy, C. Pothoulakis, G. Hamilton, J. Zacherl, G. Bischof, and et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro J Clin Invest 95 1995 2004 2011
7. H.H. Locher, P. Seiler, X. Chen, S. Schroeder, P. Pfaff, M. Enderlin, and et al. In vitro and in vivo antibacterial evaluation of cadazolid, a new antibiotic for treatment of Clostridium difficile infections Antimicrob Agents Chemother 58 2014 892 900
8. M.U. Rashid, H.M. Lozano, A. Weintraub, and C.E. Nord In vitro activity of cadazolid against Clostridium difficile strains isolated from primary and recurrent infections in Stockholm, Sweden Anaerobe 20 2013 32 35
9. H.H. Locher, P. Caspers, T. Bruyere, S. Schroeder, P. Pfaff, A. Knezevic, and et al. Investigations of the mode of action and resistance development of cadazolid, a new antibiotic for treatment of Clostridium difficile infections Antimicrob Agents Chemother 58 2014 901 908
10. C.H. Chilton, G.S. Crowther, S.D. Baines, S.L. Todhunter, J. Freeman, H.H. Locher, and et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection J Antimicrob Chemother 69 2014 697 705
11. D. Baldoni, M. Gutierrez, W. Timmer, and J. Dingemanse Cadazolid, a novel antibiotic with potent activity against Clostridium difficile: safety, tolerability and pharmacokinetics in healthy subjects following single and multiple oral doses J Antimicrob Chemother 69 2014 706 714
12. T.J. Louie, C.E. Nord, G.H. Talbot, M. Wilcox, D.N. Gerding, M. Buitrago, and et al. Multicentre, double-blind, randomised, phase 2 study evaluating the novel antibiotic, cadazolid, in subjects with Clostridium difficile-associated diarrhoea 23rd European congress of clinical microbiology and infectious diseases (ECCMID) 2013 ESCMID 27-30 April 2013, Berlin, Germany LB2956
13. M.P. Bauer, E.J. Kuijper, J. van Dissel European Society of Clinical Microbiology and Infectious Diseases European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDI) Clin Microbiol Infect 15 2009 1067 1079
14. R. Gerhard, S. Nottrott, J. Schoentaube, H. Tatge, A. Olling, and I. Just Glucosylation of Rho GTPases by Clostridium difficile toxin A triggers apoptosis in intestinal epithelial cells J Med Microbiol 57 2008 765 770
15. N.W. Read, C.A. Miles, D. Fisher, A.M. Holgate, N.D. Kime, and M.A. Mitchell Transit of a meal through the stomach, small intestine, and colon in normal subjects and its role in the pathogenesis of diarrhea Gastroenterology 79 1980 1276 1282